Latest Content by PharmaCompass
About
Industry Trade Show
Not Confirmed
17-20 March, 2025
Industry Trade Show
Not Confirmed
25-29 January, 2025
Industry Trade Show
Not Confirmed
27-30 January, 2025
CONTACT DETAILS
Digital content 
NEWS #PharmaBuzz
15 Jan 2025
// PRESS RELEASE
15 Jan 2025
// PRESS RELEASE
13 Jan 2025
// PRESS RELEASE
08 Jan 2025
// PRESS RELEASE
02 Jan 2025
// PRESS RELEASE
30 Dec 2024
// #N/A
Drugs in Development
Lead Product(s) : Antibody
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Abilita Therapeutics
Deal Size : $785.0 million
Deal Type : Collaboration
Orion, Abilita Collaborate on Antibody Therapeutics With Licensing Options
Details : The collaboration combines Abilita's strength in discovering breakthrough antibody therapeutics for challenging membrane protein targets with Orion's proven expertise in oncology, pain.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 18, 2024
Lead Product(s) : Bispecific Antibody
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Alligator Bioscience
Deal Size : $3.6 million
Deal Type : Collaboration
Orion and Alligator Bioscience Amend their Agreement Concerning Two Bispecific Antibodies
Details : Orion will continue to developtwo bispecific antibodies, which are currently in late-stage pre-clinical development, successfully developed using Alligator’s RUBY bispecific format.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 19, 2024
Orion Terminates ODM-111 Program Due To Narrow Therapeutic Window Challenges
Details : ODM-111 is NaV. 1.8 blocker was being evaluated in the early-stage clinical trial studies with the patients for the treatment of acute and chronic pain.
Brand Name : ODM-111
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2024
Lead Product(s) : Darolutamide,Androgen Deprivation Therapy
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Bayer AG
Deal Size : Not Applicable
Deal Type : Not Applicable
Bayer Submits Third EU Indication Application for Darolutamide via Orion Collaboration
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Brand Name : Nubeqa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2024
Lead Product(s) : Darolutamide,Androgen Deprivation-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Bayer AG
Deal Size : Not Applicable
Deal Type : Not Applicable
Bayer Submits FDA Application For Third Indication of Darolutamide
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated in combination with ADT for metastatic hormone-sensitive prostate cancer.
Brand Name : Nubeqa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Aitia
Deal Size : $10.0 million
Deal Type : Collaboration
Orion, Aitia Partner on AI-Driven Drug Discovery and Simulation in Oncology
Details : Through the collaboration, Orion and Aitia will work together to discover and validate novel drug targets and to develop drug candidates across multiple oncologic indications.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
September 25, 2024
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : $1,920.0 million
Deal Type : Licensing Agreement
Merck and Orion Mutual Option Exercise for Opevesostat in Prostate Cancer Treatment
Details : Through the license agreement, Merck will gain global rights to develop and commercialize MK-5684 (opevesostat), which is being evaluated for metastatic castration-resistant prostate cancer.
Brand Name : MK-5684
Molecule Type : Small molecule
Upfront Cash : $290.0 million
July 01, 2024
Lead Product(s) : Levosimendan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Tenax Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Tevogen Bio Prepares to Launch Genetic Predisposition Study for TVGN 489 in Long COVID
Details : Under the license agreement, Tenax will be developing and commercializing the TNX-103 (levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction.
Brand Name : TNX-103
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 20, 2024
Lead Product(s) : LCB14
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : LegoChem Biosciences
Deal Size : $410.9 million
Deal Type : Financing
LegoChemBio Joins Hands with Orion to Become a Global Top ADC Company
Details : The net proceeds will be used to advance Lego's ADC pipeline including, LCB14, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2).
Brand Name : LCB14
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Glykos
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Orion and Glykos Announce Research Collaboration for Next-Generation Adcs
Details : Under the agreement, Orion gains access to Glykos’ ADC technologies, initiating an ADC program and will be responsible for the target selection and commercialization of next-generation ADCs.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 08, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Orion Corporation
Share 
